# Jubilant Pharmova share price today (Jubilant Pharmova Ltd, NSE: JUBLPHARMA)

> Jubilant Pharmova share price today: ₹938.75 at the NSE close on 3 November 2026, down 14.5% in a year. Jubilant Pharmova (NSE: JUBLPHARMA) is worth ₹14,951 crore, trades at a P/E of 38.5 and has closed between ₹817.45 and ₹1,128.95 over the past 52 weeks. > Jubilant Pharmova Ltd's share price has risen faster than its earnings: −14.5% in a year, against −52.5% for earnings per share. JUBLPHARMA · Pharma - API & CRAMS · data as of 3 November 2026. Page: https://www.sectoralpha.in/stocks/jubilant-pharmova-ltd

Sector Alpha also publishes a daily newsletter that explains one Indian stock at a time: https://newsletter.sectoralpha.in/?utm_source=sectoralpha&utm_medium=ai_text&utm_campaign=llms

## Key numbers

- Business trend: Getting worse, from the last 12 quarters
- Price: ₹938.75 (−14.5% in a year)
- P/E: 38.5× (higher than 82% of the last 11 years)
- Revenue (Jun 2026): ₹2,229 Cr (+17.3% on a year ago)
- Profit (Jun 2026): ₹56.0 Cr (−45.1% on a year ago)
- Operating margin: 11.0% (−4.0 points on a year ago)
- ROCE: 9%, FY26
- ROIC: 5.1%, against a 12.0% cost of capital: −6.9 points

The main question: the share price moved −14.5% in a year while yearly earnings per share moved −52.5%. The difference came from the market paying a higher multiple. ## What is the Jubilant Pharmova share price today? Jubilant Pharmova Ltd's share price was ₹938.75 at the close on 3 November 2026. It has been falling for 12 weeks. That is 3.1% below its average price over the last 200 trading days. In the last 52 weeks it traded between ₹817 and ₹1,129, and at that close it sat 39% of the way up from that low. Over the past 13 weeks it has done better than the NIFTY 500, and it has stayed ahead for 4 weeks in a row. Over the last 11 years the share price moved +190% while the NIFTY 500 moved +251%, so it is behind the index over that whole period. The chart above shows the 13-week comparison for every week. This page treats a rise as over when the price closes below its 200-day average on two Fridays in a row. ## What changed at Jubilant Pharmova this quarter? Three changes stood out: indian funds and insurers (DIIs) raised their stake for 14 quarters in a row, revenue up on a year earlier for 11 quarters in a row (every quarter we can compare) and lowest operating margin in 12 quarters. 1. Indian funds and insurers (DIIs) raised their stake for 14 quarters in a row From 1.6% to 13% of the company by the September 2026 quarter. 2. Revenue up on a year earlier for 11 quarters in a row (every quarter we can compare) In the June 2026 quarter revenue was ₹2,229 crore, +17.3% on a year earlier. 3. Lowest operating margin in 12 quarters Operating margin was 11% in the June 2026 quarter, against 15% a year earlier. ## What are Jubilant Pharmova's latest quarterly results? For April to June 2026 (the quarter ended 30 June 2026), Jubilant Pharmova reported revenue of ₹2,229 crore, up 17.3% from ₹1,901 crore a year earlier, and a profit of ₹56.0 crore, down 45.1% from ₹102 crore. ### Jubilant Pharmova results: April to June 2026 against a year earlier

| Measure | April to June 2026 | April to June 2025 | Change |
| --- | --- | --- | --- |
| Revenue | ₹2,229 crore | ₹1,901 crore | +17.3% |
| Profit | ₹56.0 crore | ₹102 crore | −45.1% |
| Earnings per share | ₹3.55 | ₹6.46 | −45.0% |
| Operating margin | 11.0% | 15.0% | −4.0 points |

The next results, for July to September 2026, are due by 14 November 2026: listed companies must publish quarterly results within 45 days of the quarter's end (60 days for the January to March quarter). The newest call in our records is from 22 May 2026, about January to March 2026; a call about these results is not in our records yet. (From the company's reported quarterly results (quarter ended 30 June 2026). Revenue and profit in ₹ crore.)

## What is the Jubilant Pharmova share price history? Jubilant Pharmova closed at ₹938.75 on 3 November 2026, down 14.5% from ₹1,097.55 a year earlier (31 October 2025) and up 54.0% over five years. Its highest weekly close since March 2016 was ₹1,264.00 on 1 November 2024. ### Jubilant Pharmova share price: then and now

| When | Close | Change to 3 Nov 2026 |
| --- | --- | --- |
| 1 week ago · 23 Oct 2026 | ₹937.85 | +0.1% |
| 1 month ago · 1 Oct 2026 | ₹1,000.65 | −6.2% |
| 6 months ago · 30 Apr 2026 | ₹926.75 | +1.3% |
| 1 year ago · 31 Oct 2025 | ₹1,097.55 | −14.5% |
| 3 years ago · 3 Nov 2023 | ₹395.00 | +137.7% |
| 5 years ago · 4 Nov 2021 | ₹609.40 | +54.0% |
| 10 years ago · 4 Nov 2016 | ₹553.54 | +69.6% |
| Earliest weekly close in our records · 11 Mar 2016 | ₹324.04 | +189.7% |
| Highest weekly close since March 2016 · 1 Nov 2024 | ₹1,264.00 | −25.7% |
| Lowest weekly close since March 2016 · 27 Mar 2020 | ₹230.76 | +306.8% |
| 52-week high (weekly close) · 14 Nov 2025 | ₹1,128.95 | −16.8% |
| 52-week low (weekly close) · 6 Mar 2026 | ₹817.45 | +14.8% |

Weekly closing prices. Each change is the move from that price to the 3 Nov 2026 close. A day's intraday high or low can go beyond these weekly closes. (563 weekly closes from 11 March 2016 to 3 November 2026.)

## What is the latest news on Jubilant Pharmova? 3 Nov 2026: Jubilant Pharmova closed at ₹938.75, up 0.1% on the week and down 6.2% on the month. 24 Jul 2026: ex-date for a dividend of ₹5 a share. ### Earlier

- Results for April to June 2026: Revenue up 17.3% and profit down 45.1% on a year earlier. - 22 May 2026: Jubilant Pharmova held its results call for January to March 2026. Management guided: FY27 consolidated growth momentum to strengthen. ## What dividend does Jubilant Pharmova pay? Jubilant Pharmova paid ₹5 a share in regular dividends in the 12 months to 4 November 2026 (1 payment), a yield of 0.53% at the ₹938.75 close on 3 November 2026. The last was a dividend of ₹5 a share, ex-date 24 July 2026. ### Jubilant Pharmova dividends since 1 April 2021

| Ex-date | Dividend per share | Type | Record date |
| --- | --- | --- | --- |
| 24 Jul 2026 | ₹5 | Dividend | same day |
| 25 Jul 2025 | ₹5 | Dividend | same day |
| 2 Aug 2024 | ₹5 | Dividend | same day |
| 10 Aug 2023 | ₹5 | Dividend | same day |
| 11 Aug 2022 | ₹5 | Dividend | 12 Aug 2022 |
| 5 Aug 2021 | ₹5 | Dividend | 6 Aug 2021 |

Amounts as the company declared them on the NSE. A dividend goes to whoever owns the shares before the ex-date. 5 of 5 Of the last 5 financial years, years with an NSE dividend record

Yes. Jubilant Pharmova Ltd paid out 20% of its profit as dividends in FY26, and it paid a dividend in 11 of its last 13 reported years. 2 of those years show a negative figure because profit itself was negative. (From the NSE corporate-actions record, read 4 November 2026.)

## What did Jubilant Pharmova management say on the latest results call? On the call for January to March 2026, held on 22 May 2026, Jubilant Pharmova's management guided: FY27 consolidated growth momentum to strengthen. > “We expect to reach peak revenue in Line 3 in 1.5 to 2 years earlier than projected and achieve 80-90 million specifically for Line 3”
> Chris Pretty, CEO CDMO Sterile Injectables, on the call for January to March 2026

### What management guided

- FY27 operating margin two-halves story: H1 pressured by SPECT shortage, H2 recovery to 17-18% range. - Line 3 commercial production late FY27, tech transfer revenue 60-80 million FY27. - Line 3 peak revenue 80-90 million reached 1.5-2 years earlier than originally projected. - Radiopharma FY27: low double-digit revenue growth, operating margin 38-40%. Management’s own plans and goals, from our notes of the call. A plan is not a result. Source: [the call transcript](https://files.tijorifinance.com/insight/india/3108/Conference Call/CC-May26.pdf). (From the call for January to March 2026, 22 May 2026. The April to June 2026 results are out since, so this part may be out of date until we update it.)

## What to watch in Jubilant Pharmova's next results? When Jubilant Pharmova reports July to September 2026, these are the 4 checks that show whether the story is still on course. First: Line 3 commercial production confirmation by late FY27 and tech transfer revenue realization of 60-80 million; falsifiable against future earnings reports. - What to check (from the call)
- Line 3 commercial production confirmation by late FY27 and tech transfer revenue realization of 60-80 million; falsifiable against future earnings reports. - MIBG full NDA filing H2 FY27 and FDA accelerated review clock commencement; regulatory milestone gates commercialization visibility and timeline confidence. - H2 FY27 operating margin recovery to 17-18% as SPECT supply normalizes and Line 3 tech transfer revenue flows; validates or invalidates management margin recovery narrative. - Montreal loss trajectory execution: FY27 tracking ₹200 crore, FY28 cost reduction delivering meaningful improvement; tests credibility of turnaround plan and H1 FY27 disclosure accuracy. ## Which stock lists is Jubilant Pharmova on? Jubilant Pharmova is on 2 of our India lists: Small & mid cap stocks and Pharma stocks. - [Small & mid cap stocks Size rank in India: 435](https://www.sectoralpha.in/small-cap-stocks-india)
- [Pharma stocks Market value (₹ crore): 15081.59017103269](https://www.sectoralpha.in/sectors/pharma-stocks-india)

## Is Jubilant Pharmova profitable? Jubilant Pharmova Ltd earned ₹56.0 Cr of net profit in the Jun 2026 quarter, −45.1% on the same quarter a year earlier. Full-year FY26 profit was ₹398 Cr. Over 10 years profit has grown 0.3% a year on average. That is 2.5% of the quarter's revenue. The same quarter a year earlier earned ₹102 Cr. 1 of the last 12 reported quarters were loss-making. For the full year, FY26 profit was ₹398 Cr (−52.4% on the year before). Why profit moved: revenue changed +17.3% on a year earlier and the margin moved −4.0 percentage points. Sales did the work while the margin got thinner. On average over the last four quarters, profit changed −23.3% and revenue +16.2%. Profit is growing slower than sales: rising costs are taking part of the growth. ## How much revenue does Jubilant Pharmova make, and is it growing? Jubilant Pharmova Ltd reported ₹2,229 Cr of revenue in the Jun 2026 quarter, +17.3% on the same quarter a year earlier. That is the 12th quarter in a row with growth on the year before. Over 10 years it has grown 3.7% a year on average. The last full year, FY26, came in at ₹8,280 Cr. The last four reported quarters add to ₹8,607 Cr. FY26 revenue was ₹8,280 Cr, +14.5% on the year before. Recent pace: the last four quarters grew +16.2% on average, against 3.7% a year over the longer run, so this year is growing faster than its own long-run rate. Is growth speeding up? Revenue over the last 12 months grew +16.2%, against +12.1% a year over the last 8 quarters (accelerating); profit over the last 12 months grew −23.0%, against −20.0% a year (stabilising). ## How much of every ₹100 of sales does Jubilant Pharmova keep? Jubilant Pharmova Ltd's operating margin was 11.0% in the Jun 2026 quarter, 4.0 percentage points lower than the same quarter a year ago. Across 13 years it has been between 11.0% and 26.0%. The latest quarter is within that range. Why the margin moved: operating margin changed −4.1 percentage points on the year while gross margin changed −1.1 points. So the drop came mostly from costs below the gross margin, such as staff and overheads, measured against sales. ## Is Jubilant Pharmova's profit turning into cash? Over the last 3 years, 250% of Jubilant Pharmova Ltd's reported profit came in as cash from its operations, so the profit is backed by cash. In FY26 it brought in ₹1,227 Cr of operating cash against ₹398 Cr of profit. After ₹2,640 Cr of spending on assets, free cash was −₹1,413 Cr: it spent more than its operations brought in. Cash-flow figures here are yearly, because quarterly cash statements are not published, so this section changes once a year. Why 250% of profit came in as cash: the cash cycle got 147 days shorter between FY21 and FY26, so cash that used to wait in the business now arrives sooner. What to look at next: the bigger use of cash is spending on new assets, at 4.6× depreciation over three years. The next section checks what that spending is building. ## Where does Jubilant Pharmova's cash go? Jubilant Pharmova Ltd's cash cycle, the days between paying suppliers and getting paid by customers, was 47 days in FY26, down from 194 days in FY21. It spent ₹5,452 Cr on assets over the last 3 years. Customers take 47 days to pay, and stock sits for 170 days on average. At FY26 sales of ₹8,280 Cr, each day of that cycle ties up about ₹22.7 Cr, so roughly ₹1,066 Cr is tied up in the business at any time. FY26: customers took 47 days to pay and stock sat for 170 days, about 5.6 months of sales sitting as stock, for a full cycle of 47 days, shorter than FY21's 194. The full loop: cash goes out to suppliers and production on day 0. Stock sits for 170 days. Customers pay about 47 days after that. Suppliers are paid at 170 days. Together that makes the 47-day cycle. Spending on assets: ₹5,452 Cr over the last 3 years, against ₹1,191 Cr of depreciation (the yearly wear and tear on existing assets). So it is building well beyond replacing what wears out. Work still in progress is ₹4,040 Cr (FY26): assets paid for that are not earning yet. In short: the cash is going into new capacity, not getting stuck in the daily cycle. The question is whether the new capacity earns. ## What is Jubilant Pharmova's P/E ratio, and how does it compare with its own history? Jubilant Pharmova Ltd's P/E is 38.5×, near the high end of its own history: higher than 82% of past readings. Its usual P/E (the middle reading) is 17.1×, over 11 years of weekly prices. This compares the share price with the company’s own past. It does not say what the business is worth. The P/E here, and its history, use a profit figure that can leave out one-off items, so it can differ from a P/E worked out on the quarterly results. Those results' earnings per share for the four quarters to Jun 2026 add up to ₹22.11. Why the multiple is where it is: over the past year earnings per share moved −52.5% while the price moved −14.5%. The price did better than earnings, which pushed the multiple up within its own range. Where the price move came from: over 5 years the price moved +9.0% a year; about −14.3% a year came from earnings growth and about +23.3 percentage points from the multiple (the market paying more); over 10 years the price moved +5.4% a year; about −1.3% a year came from earnings growth and about +6.7 percentage points from the multiple (the market paying more). The split is approximate (price return minus earnings growth). It shows how much of the move came from the market paying a different multiple. In short: the multiple is high against its own past, so the earnings trend underneath matters more than the multiple. ## Is the Jubilant Pharmova business getting better or worse? Jubilant Pharmova Ltd's business is getting worse. Profit and EPS growth are shrinking: profit growth is −23.0% in the latest quarter, against +1732.4% at its best in 12 quarters, with ROCE steady at 6.5%. This is based on 12 quarters of 4 measures. Why it matters: falling lines mean any ratio below that looks low should be read with that direction in mind. ## How much does Jubilant Pharmova earn on its capital? Jubilant Pharmova Ltd earned a ROCE of 9% in FY26. That is up from a low of 3% in FY23. Its return on capital used (ROIC) is 6.9 percentage points below its cost of capital, so growth here does not yet pay for the capital it uses. It comes from a 4.8% net margin and 0.54× asset turnover (sales divided by assets). Why the return is what it is (FY26): a 4.8% net margin × 0.54× asset turnover × 2.15× leverage (assets divided by equity) ≈ 5.6% on equity. The margin does its share; borrowing is a big part of it. The key test, return on capital used minus the cost of capital: 5.1% − 12.0% = −6.9 percentage points. The 12.0% is a standard assumption for the cost of capital in India, not an estimate for this company. Read the sign and size of the gap, not the decimals. Negative: growth at these returns loses value until returns improve. The 5.1% ROIC above is the latest reading, as reported. The yearly chart below shows FY26 at 6.1%, and the quarterly chart works out each 12-month window from the quarterly figures, so the readings differ by date, not by method. ## Does Jubilant Pharmova have too much debt? Jubilant Pharmova Ltd has total debt of ₹3,615 Cr against shareholder equity of ₹7,096 Cr as of Jun 2026, so its debt is 0.51× its equity. Year by year, that ratio went from 0.60 in FY22 to 0.51 in FY26. Keep that borrowing in mind when reading the returns on this page. ## What is the Jubilant Pharmova shareholding pattern? Domestic institutions raised their stake in Jubilant Pharmova Ltd by 7.3 percentage points over 8 quarters, the biggest change among its owners. Domestic institutions now own 13.0% of the company. Promoters moved −3.0 points over the same period, to 47.7%. This uses the four owner groups that companies report every quarter; nothing is guessed between filings. Over the last two years: Domestic institutions: +7.3 points over 8 quarters, to 13.0%; Promoters: −3.0 points over 8 quarters, to 47.7%; Foreign institutions: −2.6 points over 8 quarters, to 15.4%. Why the owners changed: foreign institutions moved −2.6 points and domestic institutions +7.3 points over 8 quarters, while promoters moved −3.0 points. One group of institutions took over shares from the other; it is not a change of mind by the people running the company. ## How far is Jubilant Pharmova from balance-sheet trouble? For Jubilant Pharmova Ltd, the Z-score is not available, so we say so rather than guess one. It estimates how far the balance sheet is from trouble; it is not a forecast of failure. The debt, cash-flow and return sections show the balance-sheet figures we do have, each with its own date. ## How does Jubilant Pharmova rank in its industry? 30.3 out of 100, rank 19 of 24 in Pharma - API & CRAMS, with 86% of the evidence available. Jubilant Pharmova Ltd scores 30.3 out of 100 against the 24 companies it is compared with in Pharma - API & CRAMS, ranking 19. The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. The four parts add up to the total exactly: 10.6 + 6.2 + 10.2 + 3.3 = 30.3. This is the same number shown on the industry page; it is worked out once for the whole group and read here. What would change it: The score would fall if profit growth turns negative or margins stop improving while the share price lags its sector. ## Which companies is Jubilant Pharmova compared with? Jubilant Pharmova ranks 19 of 24 Pharma - API & CRAMS companies on the 4-Factor Sector Score, with 30.3 out of 100. 1. [Neuland Laboratories Ltd](https://www.sectoralpha.in/stocks/neuland-laboratories-ltd) NEULANDLAB · leader · Most evidence points up · 96% evidence 76.0 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 32.3/35 · Revenue 78.3% · Profit 100% · Operating margin change 23 points · 88% evidence Capital efficiency 22.9/25 · ROCE 26.5% · Operating margin 35% · 100% evidence Valuation 14.1/20 · P/E 50.8× · PEG 1.04 · 100% evidence Relative strength 6.7/20 · Lead over its industry -7.8% · Lead over NIFTY 500 20.3% · 1 year 19.6% · 100% evidence · 12 of 12 weeks ahead Exact sum: 32.3 + 22.9 + 14.1 + 6.7 = 76 · What this means: Earnings are strong; relative strength in its sector is -7.8% and the one-year return is 19.6%. 2. [Acutaas Chemicals Ltd](https://www.sectoralpha.in/stocks/acutaas-chemicals-ltd) ACUTAAS · turning · Most evidence points up · 67% evidence 73.9 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 31.3/35 · Revenue 45.4% · Profit 95.5% · Operating margin change 9 points · 95% evidence Capital efficiency 20.3/25 · ROCE 31.6% · Operating margin 40% · 76% evidence Valuation 10.2/20 · P/E 74.6× · PEG n/a · 50% evidence Relative strength 12.1/20 · Lead over its industry n/a · Lead over NIFTY 500 59.6% · 1 year 131.7% · 25% evidence · 2 of 9 weeks ahead Exact sum: 31.3 + 20.3 + 10.2 + 12.1 = 73.9 · What this means: Earnings, capital efficiency and relative strength all agree. The open questions are about management, upcoming events and risks. 3. [Laurus Labs Ltd](https://www.sectoralpha.in/stocks/laurus-labs-ltd) LAURUSLABS · leader · Most evidence points up · 93% evidence 71.0 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 30.9/35 · Revenue 23% · Profit 95.3% · Operating margin change 10 points · 100% evidence Capital efficiency 17.3/25 · ROCE 17.8% · Operating margin 34% · 100% evidence Valuation 5.8/20 · P/E 97× · PEG 2.98 · 65% evidence Relative strength 17.0/20 · Lead over its industry 42.3% · Lead over NIFTY 500 82.8% · 1 year 152.2% · 100% evidence · 12 of 12 weeks ahead Exact sum: 30.9 + 17.3 + 5.8 + 17 = 71 · What this means: Earnings, capital efficiency and relative strength all agree. The open questions are about management, upcoming events and risks. 4. [Gland Pharma Ltd](https://www.sectoralpha.in/stocks/gland-pharma-ltd) GLAND · leader · Most evidence points up · 96% evidence 69.9 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 25.0/35 · Revenue 17.6% · Profit 46.4% · Operating margin change 3 points · 88% evidence Capital efficiency 16.0/25 · ROCE 15.1% · Operating margin 27% · 100% evidence Valuation 12.1/20 · P/E 44.6× · PEG 1.45 · 100% evidence Relative strength 16.8/20 · Lead over its industry 15.1% · Lead over NIFTY 500 49.3% · 1 year 60.5% · 100% evidence · 12 of 12 weeks ahead Exact sum: 25 + 16 + 12.1 + 16.8 = 69.9 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 5. [IOL Chemicals & Pharmaceuticals Ltd](https://www.sectoralpha.in/stocks/iol-chemicals-pharmaceuticals-ltd) IOLCP · leader · Most evidence points up · 100% evidence 69.7 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 29.1/35 · Revenue 26.7% · Profit 75% · Operating margin change 4 points · 100% evidence Capital efficiency 12.8/25 · ROCE 11.3% · Operating margin 14% · 100% evidence Valuation 13.9/20 · P/E 24.6× · PEG 0.66 · 100% evidence Relative strength 13.9/20 · Lead over its industry 21.6% · Lead over NIFTY 500 53.8% · 1 year 92.1% · 100% evidence · 12 of 12 weeks ahead Exact sum: 29.1 + 12.8 + 13.9 + 13.9 = 69.7 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 6. [Shilpa Medicare Ltd](https://www.sectoralpha.in/stocks/shilpa-medicare-ltd) SHILPAMED · leader · Most evidence points up · 89% evidence 67.0 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 26.4/35 · Revenue 28% · Profit 100% · Operating margin change 1 points · 88% evidence Capital efficiency 10.8/25 · ROCE 10.9% · Operating margin 29% · 100% evidence Valuation 9.9/20 · P/E 65.7× · PEG 1.73 · 65% evidence Relative strength 19.9/20 · Lead over its industry 47.2% · Lead over NIFTY 500 84.2% · 1 year 170.8% · 100% evidence · 12 of 12 weeks ahead Exact sum: 26.4 + 10.8 + 9.9 + 19.9 = 67 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 7. [Morepen Laboratories Ltd](https://www.sectoralpha.in/stocks/morepen-laboratories-ltd) MOREPENLAB · leader · Evidence leans up · 85% evidence 62.1 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 31.8/35 · Revenue 30.1% · Profit 90.9% · Operating margin change 9 points · 100% evidence Capital efficiency 9.3/25 · ROCE 8.1% · Operating margin 16% · 100% evidence Valuation 8.5/20 · P/E 32.9× · PEG 2.14 · 100% evidence Relative strength 12.5/20 · Lead over its industry n/a · Lead over NIFTY 500 94.5% · 1 year 139% · 25% evidence · 12 of 12 weeks ahead Exact sum: 31.8 + 9.3 + 8.5 + 12.5 = 62.1 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 8. [Divis Laboratories Ltd](https://www.sectoralpha.in/stocks/divis-laboratories-ltd) DIVISLAB · leader · Evidence leans up · 96% evidence 61.4 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 24.7/35 · Revenue 16.4% · Profit 26.8% · Operating margin change 11 points · 88% evidence Capital efficiency 18.6/25 · ROCE 22% · Operating margin 41% · 100% evidence Valuation 2.6/20 · P/E 87.1× · PEG 3.45 · 100% evidence Relative strength 15.5/20 · Lead over its industry 9.2% · Lead over NIFTY 500 43.1% · 1 year 45.1% · 100% evidence · 12 of 12 weeks ahead Exact sum: 24.7 + 18.6 + 2.6 + 15.5 = 61.4 · What this means: Earnings, capital efficiency and relative strength all agree. The open questions are about management, upcoming events and risks. 9. [Granules India Ltd](https://www.sectoralpha.in/stocks/granules-india-ltd) GRANULES · turning · Evidence leans up · 96% evidence 57.4 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 24.3/35 · Revenue 24.8% · Profit 38.1% · Operating margin change 3 points · 88% evidence Capital efficiency 16.2/25 · ROCE 15.5% · Operating margin 23% · 100% evidence Valuation 10.2/20 · P/E 35.2× · PEG 1.29 · 100% evidence Relative strength 6.7/20 · Lead over its industry -5.2% · Lead over NIFTY 500 24.2% · 1 year 48.5% · 100% evidence · 7 of 12 weeks ahead Exact sum: 24.3 + 16.2 + 10.2 + 6.7 = 57.4 · What this means: Earnings are strong; relative strength in its sector is -5.2% and the one-year return is 48.5%. 10. [Sai Life Sciences Ltd](https://www.sectoralpha.in/stocks/sai-life-sciences-ltd) SAILIFE · leader · Evidence leans up · 89% evidence 57.3 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 21.7/35 · Revenue 17.6% · Profit 48% · Operating margin change 3 points · 88% evidence Capital efficiency 17.0/25 · ROCE 19.6% · Operating margin 27% · 100% evidence Valuation 4.8/20 · P/E 90× · PEG 3.63 · 65% evidence Relative strength 13.8/20 · Lead over its industry 9.9% · Lead over NIFTY 500 42.9% · 1 year 69.6% · 100% evidence · 12 of 12 weeks ahead Exact sum: 21.7 + 17 + 4.8 + 13.8 = 57.3 · What this means: A strong business with a high valuation: it would need rising earnings, or a lower multiple, to score better on value. 11. [SMS Pharmaceuticals Ltd](https://www.sectoralpha.in/stocks/sms-pharmaceuticals-ltd) SMSPHARMA · breaking out · Evidence leans up · 96% evidence 55.8 out of 100 Growth Capital Valuation Relative
12. [Blue Jet Healthcare Ltd](https://www.sectoralpha.in/stocks/blue-jet-healthcare-ltd) BLUEJET · quiet · Evidence leans up · 81% evidence 52.7 out of 100 Growth Capital Valuation Relative
13. [Solara Active Pharma Sciences Ltd](https://www.sectoralpha.in/stocks/solara-active-pharma-sciences-ltd) SOLARA · breaking out · Evidence leans down · 74% evidence 49.5 out of 100 Growth Capital Valuation Relative
14. [Windlas Biotech Ltd](https://www.sectoralpha.in/stocks/windlas-biotech-ltd) WINDLAS · leader · Evidence leans down · 81% evidence 47.6 out of 100 Growth Capital Valuation Relative
15. [Anthem Biosciences Ltd](https://www.sectoralpha.in/stocks/anthem-biosciences-ltd) ANTHEM · leader · Evidence leans down · 89% evidence 46.7 out of 100 Growth Capital Valuation Relative
16. [Piramal Pharma Ltd](https://www.sectoralpha.in/stocks/piramal-pharma-ltd) PPLPHARMA · leader · Evidence leans down · 71% evidence 44.6 out of 100 Growth Capital Valuation Relative
17. [Supriya Lifescience Ltd](https://www.sectoralpha.in/stocks/supriya-lifescience-ltd) SUPRIYA · breaking out · Evidence leans down · 96% evidence 43.7 out of 100 Growth Capital Valuation Relative
18. [Concord Biotech Ltd](https://www.sectoralpha.in/stocks/concord-biotech-ltd) CONCORDBIO · quiet · Evidence leans down · 85% evidence 40.8 out of 100 Growth Capital Valuation Relative
19. Jubilant Pharmova Ltd this page JUBLPHARMA · turning · Most evidence points down · 86% evidence 30.3 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 10.6/35 · Revenue 16.3% · Profit -23% · Operating margin change -4 points · 88% evidence Capital efficiency 6.2/25 · ROCE 9% · Operating margin 11% · 100% evidence Valuation 10.2/20 · P/E 37.9× · PEG n/a · 50% evidence Relative strength 3.3/20 · Lead over its industry -25.3% · Lead over NIFTY 500 0.2% · 1 year -15.7% · 100% evidence · 6 of 12 weeks ahead Exact sum: 10.6 + 6.2 + 10.2 + 3.3 = 30.3 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 20. [Hikal Ltd](https://www.sectoralpha.in/stocks/hikal-ltd) HIKAL · turning · Most evidence points down · 78% evidence 29.7 out of 100 Growth Capital Valuation Relative
21. [OneSource Specialty Pharma Ltd](https://www.sectoralpha.in/stocks/onesource-specialty-pharma-ltd) ONESOURCE · turning · Most evidence points down · 83% evidence 29.2 out of 100 Growth Capital Valuation Relative
22. [Syngene International Ltd](https://www.sectoralpha.in/stocks/syngene-international-ltd) SYNGENE · turning · Most evidence points down · 100% evidence 27.8 out of 100 Growth Capital Valuation Relative
23. [Cohance Lifesciences Ltd](https://www.sectoralpha.in/stocks/cohance-lifesciences-ltd) COHANCE · breaking out · Most evidence points down · 78% evidence 27.1 out of 100 Growth Capital Valuation Relative
24. [Dishman Carbogen Amcis Ltd](https://www.sectoralpha.in/stocks/dishman-carbogen-amcis-ltd) DCAL · basing · Most evidence points down · 64% evidence 27.0 out of 100 Growth Capital Valuation Relative

Missing figures are not scored as bad. They lower the confidence and pull the final score toward the middle. Relative strength counts only when the company has a reading for this week; with no reading, that factor is left out and its 20 points are shared across the other three in proportion. PEG is not shown when the ratio cannot mean anything: the company must be making a profit, its price-to-earnings must be positive, and its three-year earnings growth must fall between 5% and 60%. Dividing a price multiple by a loss, or by growth measured off a tiny base, produces a number that looks precise and tells you nothing. Under relative strength, one mark per week shows the last 12 weeks: a mark is filled where the company led NIFTY 500 by 5% or more over the 13 weeks ending that week, which is the same test used everywhere on this site. Price stage places the company on the same six-step path the industry is placed on (basing, turning, breaking out, leader, fading, asleep), read from how many weeks running it has led NIFTY 500 and whether that lead is growing or shrinking. It describes where the share price stands, not the direction of earnings, and it is not a recommendation; it is left blank for a company whose weekly history is too short or too stale to read. The figures in this ranking come from the industry comparison: results through the Sep 2026 quarter, and the P/E at that quarter's end. The sections above use the latest weekly price, so a P/E or return there can differ a little from the one here. The stage words in this ranking (such as losing its lead or breaking out) describe the lead over the index, not the price phase in the price section. Related companies: [Pharma - API & CRAMS](https://www.sectoralpha.in/sectors/pharma-api-crams), all 24 compared on one page. ## Which companies are close to Jubilant Pharmova in size? Jubilant Pharmova is the 14th largest of 24 Pharma - API & CRAMS companies on Sector Alpha by market value (scores of 30 October 2026). Just above it: OneSource Specialty Pharma, Cohance Lifesciences and Syngene International. Just below it: Concord Biotech, Blue Jet Healthcare and Supriya Lifescience. ### Pharma - API & CRAMS companies close in size

1. [OneSource Specialty Pharma Ltd](https://www.sectoralpha.in/stocks/onesource-specialty-pharma-ltd) ₹17,924 crore
2. [Cohance Lifesciences Ltd](https://www.sectoralpha.in/stocks/cohance-lifesciences-ltd) ₹16,999 crore
3. [Syngene International Ltd](https://www.sectoralpha.in/stocks/syngene-international-ltd) ₹16,256 crore
4. Jubilant Pharmova Ltd ₹14,716 crore
5. [Concord Biotech Ltd](https://www.sectoralpha.in/stocks/concord-biotech-ltd) ₹13,031 crore
6. [Blue Jet Healthcare Ltd](https://www.sectoralpha.in/stocks/blue-jet-healthcare-ltd) ₹9,550 crore
7. [Supriya Lifescience Ltd](https://www.sectoralpha.in/stocks/supriya-lifescience-ltd) ₹6,819 crore

[All 24 Pharma - API & CRAMS companies, largest first](https://www.sectoralpha.in/sectors/pharma-api-crams#all-companies)

### Companies close in size in other industries

1. [IFCI Ltd](https://www.sectoralpha.in/stocks/ifci-ltd) ₹14,730 crore · Finance - PSU Lending
2. [Zydus Wellness Ltd](https://www.sectoralpha.in/stocks/zydus-wellness-ltd) ₹14,723 crore · FMCG - Personal Care
3. Jubilant Pharmova Ltd ₹14,716 crore
4. [KFin Technologies Ltd](https://www.sectoralpha.in/stocks/kfin-technologies-ltd) ₹14,710 crore · Finance - Capital Markets - RTA
5. [Poly Medicure Ltd](https://www.sectoralpha.in/stocks/poly-medicure-ltd) ₹14,692 crore · Medical Equipment

## What else do people ask about Jubilant Pharmova? ### What is Jubilant Pharmova's share price today? Jubilant Pharmova Ltd's share price is ₹938.75, −14.5% over the past year. The whole company is worth ₹14,951 Cr on the market. In the last 52 weeks it traded between ₹817 to ₹1,129; today it is 39% of the way up from the low, 3.1% below its 200-day average (as of 3 November 2026). ### What were Jubilant Pharmova's latest quarterly results? Jubilant Pharmova Ltd reported revenue of ₹2,229 Cr and net profit of ₹56.0 Cr for the Jun 2026 quarter. Revenue rose 17.3% and profit fell 45.1% compared with a year earlier. Earnings per share were ₹3.55. The operating margin was 11.0%, 4.0 percentage points lower than a year earlier (as of 3 November 2026). ### What is Jubilant Pharmova's market cap? Jubilant Pharmova Ltd's market capitalisation is ₹14,951 Cr at a share price of ₹938.75. Market cap is the share price times the number of shares, so it changes whenever the price moves (as of 3 November 2026). ### How is Jubilant Pharmova performing? Jubilant Pharmova Ltd's share price has been falling for 12 weeks. In its latest quarter, revenue rose 17.3% and profit fell 45.1% compared with a year earlier. Over the past 13 weeks it has done better than the NIFTY 500, for 4 weeks running (as of 3 November 2026). ### Will Jubilant Pharmova's share price go up? This page does not forecast Jubilant Pharmova Ltd's share price. What it shows instead: the share price is ₹938.75, and it has been falling for 12 weeks. Its P/E of 38.5× is higher than 82% of its own last 11 years (as of 3 November 2026). ### Does Jubilant Pharmova have too much debt? Jubilant Pharmova Ltd has a moderate amount of debt: its debt is 0.51× its equity, and its operating profit is 6 times its interest bill. FY26 borrowings were ₹3,615 Cr against equity of ₹7,093 Cr. Keep that borrowing in mind when reading the returns on this page (as of 3 November 2026). ### Where is Jubilant Pharmova in its business cycle? Jubilant Pharmova Ltd's FY26 operating margin was 15.0%, against a 13-year range of 11.0% to 26.0%: the middle of its own range, neither a peak nor a low. The latest quarter was 11.0%. Comparing margins with a company's own long history is a good way to see where it is in its cycle (as of 3 November 2026). ### What could break the Jubilant Pharmova story? The main question: the share price moved −14.5% in a year while yearly earnings per share moved −52.5%. The difference came from the market paying a higher multiple. On price, this page treats a rise as over when the share price closes below its 200-day average on two Fridays in a row (as of 3 November 2026). ### Is Jubilant Pharmova a stock worth studying right now? What the numbers show: Jubilant Pharmova Ltd's share price has risen faster than its earnings: −14.5% in a year, against −52.5% for earnings per share. The main open question: whether earnings grow into a price that has already moved. Every number on this page is worked out by code from the published figures, with no forecasts and no price opinions (as of 3 November 2026). ### Is there a Jubilant Pharmova share price forecast for 2026? What management itself guided: FY27 consolidated growth momentum to strengthen. ## Lists

- Small & mid cap stocks: https://www.sectoralpha.in/small-cap-stocks-india
- Pharma stocks: https://www.sectoralpha.in/sectors/pharma-stocks-india

This is research, not advice. We’re not SEBI-registered.